Mizuho lowered the firm’s price target on Fortrea (FTRE) to $8 from $10 and keeps a Neutral rating on the shares. The company reported a good Q1 earnings beat, but reported weaker than expected bookings trends driven by delays in awards for biotech clients and soft demand in clinical pharmacology, the analyst tells investors in a research note. The firm expects the funding backdrop and volatile macroeconomic environment coupled with the loss of its CEO to continue to put pressure on Fortrea.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FTRE: